Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
serabelisib + nab-paclitaxel
- Development stage
- Unknown
- Lead developer
- Faeth Therapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
Serabelisib + nab-paclitaxel is an investigational pharmaceutical **combination regimen** being studied for the treatment of solid tumors, including breast, pancreatic, ovarian, and endometrial cancers. **Serabelisib** is a selective small molecule inhibitor of **phosphoinositide 3-kinase alpha (PI3Kα)**, a key component of the PI3K/AKT/mTOR signaling pathway frequently activated in cancer. By inhibiting PI3Kα, serabelisib blocks proliferation, survival, and metastatic capabilities in cancer cells[2][4]. **Nab-paclitaxel** is a nanoparticle albumin-bound formulation of the microtubule inhibitor paclitaxel, which improves drug solubility, tumor delivery, and reduces certain toxicities; it exerts cytotoxic effects by stabilizing microtubules, disrupting cell division, and inducing apoptosis. The rationale for this combination is that PI3Kα inhibition may sensitize tumors to microtubule disruption, potentially enhancing anticancer efficacy[1][4].
- Brand names
- Abraxane (for nab-paclitaxel)
- Other names
- albumin-bound paclitaxel (for nab-paclitaxel)nab-paclitaxelserabelisib
02
Targets
TUBB (Tubulin (alpha and beta subunits))PIK3CA (Phosphoinositide 3-kinase alpha)
Beyond the preview
Go deeper on serabelisib + nab-paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on serabelisib + nab-paclitaxel.